Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Oct;83(15):1447-1453.
doi: 10.1007/s40265-023-01948-8.

Avacincaptad Pegol: First Approval

Connie Kang  1
Affiliations
Review

Avacincaptad Pegol: First Approval

Connie Kang. Drugs. 2023 Oct.

Abstract

Avacincaptad pegol (IZERVAY™; formerly Zimura®) is a complement C5 inhibitor that is being developed by IVERIC Bio, an Astellas company, for the treatment of geographic atrophy secondary to age-related macular degeneration. Avacincaptad pegol recently received approval for the treatment of adults with geographic atrophy secondary to age-related macular degeneration. This article summarizes the milestones in the development of avacincaptad pegol leading to this first approval for geographic atrophy secondary to age-related macular degeneration.

PubMed Disclaimer

References

    1. IVERIC Bio. IZERVAY™ (avacincaptad pegol intravitreal solution): US prescribing information. 2023. https://ivericbio.com . Accessed 12 Sep 2023.
    1. Jaffe GJ, Westby K, Csaky KG, et al. C5 inhibitor avacincaptad pegol for geographic atrophy due to age-related macular degeneration: a randomized pivotal phase 2/3 trial. Ophthalmology. 2021;128(4):576–86. - DOI - PubMed
    1. IVERIC Bio. Iveric Bio receives U.S. FDA approval for IZERVAY™ (avacincaptad pegol intravitreal solution), a new treatment for geographic atrophy [media release]. 5 Aug 2023. https://www.astellas.com/en/news/28281 .
    1. IVERIC Bio. Our science. 2023. https://ivericbio.com/our-science . Accessed 12 Sep 2023.
    1. Ophthotech Corporation. Ophthotech raises $36 million; in-licenses two compounds for macular degeneration [media release]. 21 Feb 2008. https://www.fiercebiotech.com/biotech/press-release-ophthotech-raises-36... .

Substances

LinkOut - more resources